1. Home
  2. CNX vs CRSP Comparison

CNX vs CRSP Comparison

Compare CNX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$41.90

Market Cap

5.5B

Sector

Energy

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.29

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNX
CRSP
Founded
1860
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.7B
IPO Year
1998
2016

Fundamental Metrics

Financial Performance
Metric
CNX
CRSP
Price
$41.90
$60.29
Analyst Decision
Sell
Buy
Analyst Count
9
17
Target Price
$35.78
$70.00
AVG Volume (30 Days)
2.1M
1.5M
Earning Date
04-30-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
763.33
N/A
EPS
3.98
N/A
Revenue
$2,239,134,000.00
$289,590,000.00
Revenue This Year
$0.03
$1,603.19
Revenue Next Year
$9.44
$78.75
P/E Ratio
$10.48
N/A
Revenue Growth
76.76
9169.85
52 Week Low
$27.68
$30.06
52 Week High
$43.12
$78.48

Technical Indicators

Market Signals
Indicator
CNX
CRSP
Relative Strength Index (RSI) 63.15 59.60
Support Level $36.33 $51.64
Resistance Level N/A $60.40
Average True Range (ATR) 1.55 3.18
MACD 0.20 0.90
Stochastic Oscillator 80.64 87.86

Price Performance

Historical Comparison
CNX
CRSP

About CNX CNX Resources Corporation

CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: